ACAD
34.98
0.00
0.00%
AEMD
5.11
+0.33
+6.90%
APRI
0.35
-0.048
-12.0694%
ARNA
1.74
-0.03
-1.69%
ATEC
8.63
+0.38
+4.61%
CNAT
2.11
-0.05
-2.31%
CRXM
0.27
0.00
+0.15%
CYTX
2.12
+0.03
+1.44%
DXCM
93.91
-0.11
-0.12%
GNMK
11.7
-0.08
-0.68%
HALO
12.09
-0.31
-2.50%
ILMN
179.33
-0.01
-0.01%
INNV
0.28
-0.01
-3.78%
INO
9.5
-0.24
-2.46%
ISCO
1.9
+0.1
+5.56%
ISIS
57.56
0.00
0.00%
LGND
115.78
-2.38
-2.01%
LPTN
3.89
+0.29
+8.06%
MBVX
4.72
-0.04
-0.84%
MEIP
1.69
-0.04
-2.31%
MNOV
7.1
+0.03
+0.42%
MRTX
5.88
-0.58
-8.98%
MSTX
0.127
-0.006
-4.2825%
NBIX
53.94
-0.22
-0.41%
NUVA
66.77
-1.29
-1.90%
ONCS
1.78
+0.01
+0.56%
ONVO
3.97
-0.03
-0.75%
OREX
3.46
+0.01
+0.29%
OTIC
17.65
-0.74
-4.02%
QDEL
22.71
-0.08
-0.35%
RCPT
231.96
0.00
0.00%
RGLS
3.45
+0.03
+0.88%
RMD
63.25
-0.73
-1.14%
SPHS
2.96
0.00
0.00%
SRNE
7.77
-0.1
-1.27%
TROV
4.79
+0.02
+0.42%
VICL
3.25
+0.06
+1.88%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.93
+9.77%
ACAD
34.98
0.00
0.00%
AEMD
5.11
+0.33
+6.90%
APRI
0.35
-0.048
-12.0694%
ARNA
1.74
-0.03
-1.69%
ATEC
8.63
+0.38
+4.61%
CNAT
2.11
-0.05
-2.31%
CRXM
0.27
0.00
+0.15%
CYTX
2.12
+0.03
+1.44%
DXCM
93.91
-0.11
-0.12%
GNMK
11.7
-0.08
-0.68%
HALO
12.09
-0.31
-2.50%
ILMN
179.33
-0.01
-0.01%
INNV
0.28
-0.01
-3.78%
INO
9.5
-0.24
-2.46%
ISCO
1.9
+0.1
+5.56%
ISIS
57.56
0.00
0.00%
LGND
115.78
-2.38
-2.01%
LPTN
3.89
+0.29
+8.06%
MBVX
4.72
-0.04
-0.84%
MEIP
1.69
-0.04
-2.31%
MNOV
7.1
+0.03
+0.42%
MRTX
5.88
-0.58
-8.98%
MSTX
0.127
-0.006
-4.2825%
NBIX
53.94
-0.22
-0.41%
NUVA
66.77
-1.29
-1.90%
ONCS
1.78
+0.01
+0.56%
ONVO
3.97
-0.03
-0.75%
OREX
3.46
+0.01
+0.29%
OTIC
17.65
-0.74
-4.02%
QDEL
22.71
-0.08
-0.35%
RCPT
231.96
0.00
0.00%
RGLS
3.45
+0.03
+0.88%
RMD
63.25
-0.73
-1.14%
SPHS
2.96
0.00
0.00%
SRNE
7.77
-0.1
-1.27%
TROV
4.79
+0.02
+0.42%
VICL
3.25
+0.06
+1.88%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.93
+9.77%
Home » Archive by Category

Xconomy

Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More

July 29, 2016 – 5:32 am

Quarterly biopharma earnings added a little heat to the already high summer temperatures. Amongst several companies to report this week, the biggest news came from Gilead Sciences (NASDAQ: GILD),…

[[Click headline to continue reading.]]

At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy

July 28, 2016 – 9:55 am

This week’s World Federation of Hemophilia World Congress in Orlando, FL, where researchers gathered to present the latest updates in treatments for the chronic bleeding disorder, marked the…

[[Click headline to continue reading.]]

LabCorp Boosts Prenatal Testing Presence with $371M Sequenom Deal

July 27, 2016 – 6:58 am

LabCorp, already a giant in diagnostics and laboratory testing, is building its capabilities in prenatal testing with an agreement to acquire Sequenom in a $371 million deal. Under the tender offer,…

[[Click headline to continue reading.]]

The Outbreaks Are Here, Where’s Our Response Plan?

July 25, 2016 – 1:32 pm

The news of the first Zika case in Pierce County—the 14th in Washington State—reminds us that the spread of disease is inevitable. While we don’t have in our region the kind of mosquito…

[[Click headline to continue reading.]]

Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More

July 22, 2016 – 4:12 am

The top news in biotech this week centers around one big job opening: the head seat at Biogen, now that George Scangos has announced plans to leave the company. Who takes the gig, and the strategic…

[[Click headline to continue reading.]]

With Biogen at a Crossroads, CEO Scangos to Step Down

July 21, 2016 – 5:19 am

[Updated, 9:20 a.m. ET, see below] Biogen has seen its highest highs under CEO George Scangos, but some lows too. After a year in which Biogen’s share price has fallen by more than a third and one of…

[[Click headline to continue reading.]]

Dauntless Takes Flight with New Business Model for Starting Biotechs

July 20, 2016 – 10:43 pm

First came Inception Sciences, a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. Then came COI…

[[Click headline to continue reading.]]

Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval

July 20, 2016 – 5:26 am

As the possibility of the first ever gene therapy approval in the U.S. draws closer, more gene therapy players are entering the public markets. Today, it’s San Francisco’s Audentes Therapeutics,…

[[Click headline to continue reading.]]

Synthorx Raises $10M to Expand Use of Synthetic DNA in Biologics

July 19, 2016 – 9:00 pm

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by…

[[Click headline to continue reading.]]

Evoke Pharma’s Stock Sinks on Stomach Drug’s Phase 3 Failure

July 18, 2016 – 8:30 am

Evoke Pharma is taking a hit in the markets after announcing a Phase 3 trial on a gastroinetestinal drug for diabetes patients failed to meet its goals. In early trading Monday, Evoke’s (NASDAQ:…

[[Click headline to continue reading.]]